Improving DxMultiomics, Powered by Your Choices

We're building DxMultiomics to be The Central Nexus of Biotech Intelligence. To ensure a seamless experience and continuous improvement, we utilize website analytics. These tools help us monitor site performance, understand how users navigate the platform, and identify opportunities to make your research journey more efficient. We handle this data with the utmost respect for your privacy, and you can choose what works best for you.

Polaris Quantum Biotech Unveils QuADD: Next-Generation Quantum-AI Drug Discovery Platform
_↗ polarisqb.com
News Image

Polaris Quantum Biotech (PolarisQB), a pioneer in quantum computing for the life sciences, has officially launched QuADD (Quantum-Aided Drug Design), the world's first SaaS platform to harness quantum computing and artificial intelligence for drug discovery. This platform represents a major advancement in pharmaceutical research by dramatically accelerating the process of identifying new drug candidates.

QuADD utilizes the immense power of quantum annealers to solve complex combinatorial optimization problems, allowing it to perform tasks in a matter of hours that would take classical computers a much longer time. The platform's core capability is its ability to explore an unprecedented chemical space, containing up to 10^30 theoretical molecules, to uncover novel, bioavailable, and synthesizable lead candidates. This scale is simply unreachable by traditional computational or laboratory methods.

Beyond its incredible speed and scale, QuADD is designed with a number of critical, built-in features to optimize the drug discovery process. It natively scores and refines molecules based on essential "druglike" criteria, including: Blood-brain barrier permeability, Solubility, Toxicity, Metabolic stability, Geometric fit to the protein target, Binding energy, functional groups, and orientation.

The platform's output is an optimized library of 1,000 to 10,000 molecules, a size that is ideal for both ensuring diversity and enabling rapid downstream evaluation. QuADD also includes features like scaffold-hopping and intellectual property (IP) periphery exploration to help researchers find truly novel and first-in-class leads.

Deployed as a secure and confidential SaaS platform, QuADD is globally accessible and tailored to meet the stringent needs of biotech and pharmaceutical R&D. According to PolarisQB's CEO, Dr. Shahar Keinan, the platform is "breaking the speed barrier" and aims to put the most advanced quantum and AI technology directly into the hands of the drug discovery community.

To further develop the platform and showcase its potential, PolarisQB is inviting innovative researchers, biotech companies, and academic teams to join its exclusive beta program. Participants will gain early access to QuADD's capabilities and play a crucial role in shaping the future of the technology. Interested parties can apply for a spot on the limited beta program at www.quadd.bio.

Log In
Sign Up